Cefotem-1.5 Injection

Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Pantalis 40 Injection VOCLAV 625 Rbvoc-DSR Rabeprazole Listuss - Syrup Vocalis SP Pantalis-D Listus-AM DIVOC CEFOTEM-1.5 INJ CEFTRALIS INJ
VOCLAV 625 Rbvoc-DSR Rabeprazole Listuss - Syrup Vocalis SP Pantalis-D Listus-AM DIVOC VOCLAV 625 Azivoc-500 tab Rbvoc-DSR Rabeprazole

Explore Our Prodcuts

Cefotem-1.5 Injection provides powerful and broad-spectrum antibacterial coverage for patients suffering from severe and complicated bacterial infections. Formulated with Cefotaxime (1 g) + Sulbactam (500 mg), it combines a third-generation cephalosporin with a β-lactamase inhibitor to ensure rapid bactericidal action and protection against resistant strains. This synergistic formulation enhances clinical efficacy, reduces treatment failures, and accelerates patient recovery in hospital and acute care settings.

Cefotem-1.5 is highly effective in the treatment of respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, skin and soft tissue infections, bone and joint infections, and gynecological infections. Its broad-spectrum activity against both Gram-positive and Gram-negative organisms, including β-lactamase–producing bacteria, makes it a reliable choice for clinicians managing moderate to severe infections.

Backed by clinical data, Cefotem-1.5 demonstrates superior success rates in managing multi-drug resistant infections, reducing recurrence, and ensuring faster symptomatic relief. Its parenteral formulation ensures precise dosing, high bioavailability, and rapid onset of action, making it a preferred option for hospital-based therapy.

Research & Clinical Data for Cefotem-1.5

Indications Supported by Evidence

  • Respiratory Tract Infections (CAP, HAP, Bronchitis): Demonstrated significant bacterial clearance and symptomatic improvement.
  • Urinary Tract Infections: Proven efficacy against complicated and recurrent UTIs with resistant strains.
  • Septicemia & Bacteremia: Rapid reduction in systemic infection markers with improved survival rates.
  • Intra-Abdominal Infections: Effective in peritonitis, appendicitis, and post-surgical infections.
  • Skin, Soft Tissue, Bone & Joint Infections: Strong clinical outcomes in cellulitis, osteomyelitis, and wound infections.
  • Gynecological Infections: High cure rates in pelvic inflammatory disease and post-partum infections.

Cefotem-1.5 Injection is a safe, trusted, and clinically validated therapy that delivers reliable infection control, enhances patient recovery, and supports better outcomes in critical care and hospital settings.